2022年度全球先天性心脏病领域大事记

Events in the field of global congenital heart disease in 2022

先天性心脏病(CHD)会影响到约1%的新生儿。由于医疗保健技术和政策的进步,越来越多的CHD患儿可存活至成年阶段,需要更加密切关注这些成年CHD患者的长期管理策略,这是不容忽视的公共卫生问题,特别是在发展中国家。2022年全球在CHD领域又有较大进步,在PubMed、Web of Science等数据库中可检索到2022年国际公认权威学术杂志上有21篇有关CHD的原创研究论著,其中10篇源自美国,7篇源自欧洲,2篇源自中国,1篇源自加拿大,1篇源自澳大利亚。其中,我国的2项研究主要关注了CHD及其并发症的致病机制(分别发表于Advanced Science和Microbiome),但缺乏解决CHD难题的大样本量、高质量前瞻性临床研究,这也提示在未来CHD研究领域中需要不断深耕的方向——凝聚力量,有组织地设计高质量的中国多中心研究,解决成年CHD,特别是艾森曼格综合征的问题。

Nearly 1%neonates are suffering from congenital heart disease(CHD)worldwild,with more and more patients would survive to adulthood owing to the improvement of techniques and policies.However,there are still severe public health issues about long-term management of adult CHD,especially in developing countries.In 2022,we have identified 21 original articles on CHD from international authoritative academic journal at the database PubMed,Web of Science and so on.10 of them were from America,7 from European countries,2 from China,1 from Canada and 1 from Australia.The 2 Chinese studies mainly focused on the pathogenic mechanisms of CHD and its complication(published in Advanced Science and Microbiome),while the multi-center,large-sample and high-quality clinical researches still warrant a lot in China.In that way,we should organize large-scale clinical researches in China to solve the public health problems of adult CHD,especially Eisenmenger Syndrome.Here,we briefly reviewed the primary researches on CHD in 2022.